BRCA1 and ovarian carcinoma: LNCaP and C4-2B cells are relatively more sensitive to olaparib in contrast to 22Rv1 and DU145 cells (Supplementary Fig. 1), but less sensitive when compared to BRCA1-null ovarian cancer UWB1.289 cells.